80 μg, 90 μg
Trade Name
Airsupra
Pressurised inhalation, suspension
Request Type
Registration
Drug Type
NCE
Approval Date
SFDA Approved Use
Airsupra is indicated for the as-needed treatment or prevention of bronchoconstriction and for the prevention of exacerbation in patients with asthma 18 years of age and older.
-Airsupra is also indicated for the prevention of exercise-induced bronchoconstriction in patients with asthma 18 years of age and older.
-Airsupra is also indicated for the prevention of exercise-induced bronchoconstriction in patients with asthma 18 years of age and older.